Neogenomics Logo
Menu

PanTracer™ Portfolio

The PanTracer portfolio reflects our commitment to evolving with the needs of oncology care—offering tests that are practical, powerful, and designed to support real-world clinical decisions.

 

hero anchor

PanTracer Portfolio

Guideline-driven tests for comprehensive genomic insights 

The PanTracer portfolio empowers oncologists with actionable genomic insights for confident, real-time treatment decisions. Whether you’re selecting approved targeted therapies or exploring clinical trials, working from a liquid or tissue biopsy, PanTracer ensures that you’re equipped with the insights you need.

Our test portfolio includes liquid and tissue testing for patients with advanced-stage solid tumors, offering flexible ordering options designed to maximize genomic insights. Order tests independently or as complementary tests based on your patient’s unique needs. When every answer counts, PanTracer is there to support you.

Precision oncology: Liquid and tissue CGP testing solutions for oncologists

Tissue Testing
Liquid Testing
Tissue Testing
NEO | PanTracer Pro

One order to gain comprehensive insights for therapy selection

Simplifies case management and enables a path to personalized treatment, providing comprehensive insights in a single order.

Turnaround Time:
8-10 Days

New York Approved: Yes

517-gene pan-solid 
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants Includes MSI and TMB
(DNA/RNA NGS)

HRD assessment included

Homologous recombination deficiency (HRD) status for ovarian tumors

IHC and Ancillary Testing cancer type-directed

--
NEO | PanTracer Tissue

Comprehensive tissue profiling

Broad tissue-based CGP covering 517 genes with DNA + RNA sequencing for optimized fusion detection. Aligns with clinical guidelines and requires minimal tissue, enabling personalized therapy selection and trial matching.

Turnaround Time:
8-10 Days

New York Approved: Yes

517-gene pan-solid
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants 
Includes MSI and TMB
(DNA/RNA NGS)

No HRD analysis
--
--
NEO | PanTracer Tissue + HRD

Comprehensive tissue profiling + HRD

Comprehensive tissue-based CGP with integrated HRD scoring (BRCA1/2 + GIS: LOH, TAI, LST) to guide personalized therapy—supporting precision care across the ovarian cancer continuum.

Turnaround Time:
8-10 Days

New York Approved: No

517-gene pan-solid 
tumor NGS panel

Detects: SNVs, InDels, CNVs, RNA fusions, splice variants Includes MSI and TMB
(DNA/RNA NGS)

HRD assessment included

Homologous recombination deficiency  (HRD) status for ovarian tumors

--
--
Liquid Testing
NEO | PanTracer LBx

Pan-solid tumor liquid biopsy genomic profiling

Liquid biopsy CGP analyzing 514 genes from a simple blood draw. Provides high-sensitivity ctDNA insights for real-time decisions when tissue is limited, inadequate, or not feasible.

Turnaround Time:
7 Days

New York Approved: No

514-gene liquid biopsy 
NGS panel

Detects: SNVs, InDels, CNVs, Fusions (ctDNA-based only; no RNA sequencing)

No HRD analysis
--
--

PanTracer portfolio features

dna icon

Broad, guideline-compliant CGP panels
Detection of alterations in over 500 cancer-related genes including SNVs, InDels, CNVs, fusions, MSI, TMB, and HRD status*.

dna icon

Rapid turnaround time to support timely decision-making​
Results in 8-10 days for tissue testing, and within 7 days for PanTracer LBx.

dna icon

Actionable and informative reports​​
Clear, concise reports to support rapid clinical decisions. Including relevant therapy implications and clinical trial options.

dna icon

Flexible ordering options to ensure availability of biomarker results​
Our flexible ordering options support independent tissue or liquid testing, concurrent ordering for NSCLC, or liquid testing as a reflex if tissue testing fails.

*HRD scoring is validated for primary epithelial ovarian tumors